The RAN is a collaborative international tri-center partnership having the unified goal of generating customized affinity capture reagents to all the human transcription factors. The five-year goal of the RAN is to establish a robust and efficient pipeline that will allow for reliable selection of high quality recombinant antibody (rAB) reagents that are superior in quality and are much cheaper and quicker to produce than those generated by hybridism technology. Generation of a renewable, validated and standardized set of antibody reagents would enable unprecedented studies of protein function and would accelerate research in all fields related to life sciences. The RAN will be directed by a leading group of antibody engineers who have an established track record of working collaboratively together for decades. Each of the centers will have a high throughput technology platform with the proven capabilities to generate high quality recombinant antibodies (rABs). The distributive model of the RAN centers provides for distributing individual Tasks among centers to be worked on in an Independent manner, but ultimately tied together by input/output conduits that feed back into all operations in the network. The core pieces of the pipeline have been rigorously validated and have exceptional capacity as demonstrated in our Preliminary Results. We will have established high-throughput validation procedures that assess antibody performance from affinity to activity in cells and ChIP analysis. The RAN's high throughput (HTP) pipelines will generate rABs in multiple formats using established and optimized automated phage display to 1500 human TFs provided by our collaborators and others. We will use HTP validation procedures to produce at least two rABs per transcription factor for high performance in: binding (KD <50 nM), Western blotting, immunoprecipitation (IP), immunofluorescence (IF) and chromatin immunoprecipitation (ChIP). We will distribute sequence information and open source reagents in multiple formats through multiple distribution channels. The impact of this project will be to accelerate the rate and reduce the cost of research in transcription factors (TFs) specifically and the proteome in general.

Public Health Relevance

A major limitation in biomedical research is the lack of high quality antibody affinity reagents. The goal of this research is to generate a new class of recombinant antibody reagents with superior characteristics that will effectively replace traditional antibodies based on animal immunization. They will also be produced quicker, cost less and will be renewable.

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54HG006436-02
Application #
8338454
Study Section
Special Emphasis Panel (ZRG1-BST-M (50))
Program Officer
Felsenfeld, Adam
Project Start
2011-09-26
Project End
2016-07-31
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
2
Fiscal Year
2012
Total Cost
$3,162,810
Indirect Cost
$715,462
Name
University of Chicago
Department
Biochemistry
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Koerber, James T; Hornsby, Michael J; Wells, James A (2015) An improved single-chain Fab platform for efficient display and recombinant expression. J Mol Biol 427:576-86
Bailey, Lucas J; Sheehy, Kimberly M; Hoey, Robert J et al. (2014) Applications for an engineered Protein-G variant with a pH controllable affinity to antibody fragments. J Immunol Methods 415:24-30
Paduch, Marcin; Koide, Akiko; Uysal, Serdar et al. (2013) Generating conformation-specific synthetic antibodies to trap proteins in selected functional states. Methods 60:3-14
Persson, Helena; Ye, Wei; Wernimont, Amy et al. (2013) CDR-H3 diversity is not required for antigen recognition by synthetic antibodies. J Mol Biol 425:803-11